Patient-reported outcomes and tolerability in patients receiving ripretinib versus sunitinib after treatment with imatinib in INTRIGUE, a phase 3, open-label study - Concepedia

Concepedia

Publication | Open Access

Patient-reported outcomes and tolerability in patients receiving ripretinib versus sunitinib after treatment with imatinib in INTRIGUE, a phase 3, open-label study

DOI Full Paper Access

10

Citations

20

References

2023

Year

Hans Gelderblom, Robin L. Jones, Jean‐Yves Blay, Suzanne George, Margaret von Mehren, John Zalcberg, Yoon‐Koo Kang, Albiruni Abdul Razak, Jonathan C. Trent, Steven Attia,

European Journal of Cancer

References

	Year	Citations

Page 1